Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies

Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report

The research shows 93% of global companies now cover weight-management drugs in their health insurance plans

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance

Alto Neuroscience bags new US patent for depression drug ALTO-207

ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

China nod to first homegrown BNCT cancer drug for human trials

The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials

DNA Nanorobots & AI could slash drug development times, Nanovery CEO says

DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

Redesigned brain receptor drugs show promise for depression

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold